-
公开(公告)号：EP3303303A1
公开(公告)日：2018-04-11
申请号：EP16724127.2
申请日：2016-05-16
申请人： Pfizer Inc.
发明人： CASIMIRO-GARCIA, Agustin , CONDON, Jeffrey Scott , FLICK, Andrew Christopher , GOPALSAMY, Ariamala , KIRINCICH, Steven J. , MATHIAS, John Paul , STROHBACH, Joseph Walter , XIANG, Jason Shaoyun , XING, Li Huang , WANG, Xiaolun
IPC分类号： C07D239/28 , C07D241/14 , A61K31/505 , A61P29/00
CPC分类号： C07D239/42 , A61K31/505 , A61P1/00 , A61P1/04 , A61P35/00 , C07D239/28 , C07D241/14 , C07D401/12 , C07D403/12 , C07D405/10
摘要： Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
2.发明公开BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS 审中-公开BICYCLISCHE-KONDENSIERTE HETEROARYL- ODER ARYLVERBINDUNGEN UND DEREN VERWENDUNG ALS IRAK4-INHIBITOREN
公开(公告)号：EP3126330A1
公开(公告)日：2017-02-08
申请号：EP15717250.3
申请日：2015-03-26
申请人： Pfizer Inc.
发明人： ANDERSON, David Randolph , BUNNAGE, Mark Edward , CURRAN, Kevin Joseph , DEHNHARDT, Christoph Martin , GAVRIN, Lori Krim , GOLDBERG, Joel Adam , HAN, Seungil , HEPWORTH, David , HUANG, Horng-Chih , LEE, Arthur , LEE, Katherine Lin , LOVERING, Frank Eldridge , LOWE, Michael Dennis , MATHIAS, John Paul , PAPAIOANNOU, Nikolaos , PATNY, Akshay , PIERCE, Betsy Susan , SAIAH, Eddine , STROHBACH, Joseph Walter , TRZUPEK, John David , VARGAS, Richard , WANG, Xiaolun , WRIGHT, Stephen Wayne , ZAPF, Christoph Wolfgang
IPC分类号： C07D207/26 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12
CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
摘要翻译： 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有如说明书中定义的式Ia结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：EP1651608A1
公开(公告)日：2006-05-03
申请号：EP04744013.6
申请日：2004-07-13
申请人： Pfizer Limited , PFIZER INC.
发明人： MATHIAS, John Paul
IPC分类号： C07D213/82 , C07D401/12 , C07D413/12 , C07D417/12 , A61K31/455 , A61P37/00
CPC分类号： C07D213/82 , C07D401/12 , C07D413/12 , C07D417/12
摘要： This invention relates to nicotinamide derivatives of general formuala (I) in which R1, R2, and R3 have the meanings defined herein, and to compositions containing and the uses of such derivatives as PDE4 inhibitors.
-
4.发明授权TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS 有权TRIAZOLOPYRIDINYLSULFANYLDERIVATE AS P38 MAP激酶抑制剂
公开(公告)号：EP1778686B1
公开(公告)日：2008-10-29
申请号：EP05772546.7
申请日：2005-08-09
申请人： Pfizer Limited , Pfizer, Inc.
IPC分类号： C07D471/04 , C07C321/28 , A61P29/00 , A61K31/437 , A61K31/4745
CPC分类号： C07D471/04
摘要： A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; Forumla (I) and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.
-
公开(公告)号：EP1651640B1
公开(公告)日：2007-02-14
申请号：EP04744026.8
申请日：2004-07-13
申请人： Pfizer Limited , PFIZER INC.
IPC分类号： C07D409/12 , A61P11/00 , A61P37/00 , A61K31/4436 , C07D409/14 , C07D471/04 , C07D417/14 , C07D413/14
CPC分类号： A61K31/4436 , A61K9/2018 , A61K9/2866 , A61K31/4523 , A61K31/454 , A61K31/519 , C07D213/82 , C07D409/12 , C07D409/14 , C07D417/14 , C07D471/04 , Y02A50/411
摘要： This invention relates to nicotinamide derivatives of general formula (I): in which R1, Z and R2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.
-
公开(公告)号：EP3126330B1
公开(公告)日：2019-02-27
申请号：EP15717250.3
申请日：2015-03-26
申请人： Pfizer Inc.
发明人： ANDERSON, David Randolph , BUNNAGE, Mark Edward , CURRAN, Kevin Joseph , DEHNHARDT, Christoph Martin , GAVRIN, Lori Krim , GOLDBERG, Joel Adam , HAN, Seungil , HEPWORTH, David , HUANG, Horng-Chih , LEE, Arthur , LEE, Katherine Lin , LOVERING, Frank Eldridge , LOWE, Michael Dennis , MATHIAS, John Paul , PAPAIOANNOU, Nikolaos , PATNY, Akshay , PIERCE, Betsy Susan , SAIAH, Eddine , STROHBACH, Joseph Walter , TRZUPEK, John David , VARGAS, Richard , WANG, Xiaolun , WRIGHT, Stephen Wayne , ZAPF, Christoph Wolfgang
IPC分类号： C07D207/26 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12
-
7.发明授权
公开(公告)号：EP1778686B9
公开(公告)日：2009-08-12
申请号：EP05772546.7
申请日：2005-08-09
申请人： Pfizer Limited , Pfizer, Inc.
IPC分类号： C07D471/04 , C07C321/28 , A61P29/00 , A61K31/437 , A61K31/4745
CPC分类号： C07D471/04
-
公开(公告)号：EP1651647A1
公开(公告)日：2006-05-03
申请号：EP04744024.3
申请日：2004-07-13
申请人： Pfizer Limited , PFIZER INC.
发明人： MATHIAS, John Paul
IPC分类号： C07D471/04 , C07D401/12 , A61K31/455 , A61P37/00
CPC分类号： A61K31/455 , C07D401/12 , C07D471/04
摘要： This invention relates to nicotinamide derivatives of general formula (I) in which R1, R2, and R3 have the meanings defined herein, and to compositions containing and the uses of such derivatives as PDE4 inhibitors.
摘要翻译： 本发明涉及通式（I）的烟酰胺衍生物，其中R 1，R 2和R 3具有本文定义的含义，并且涉及含有这些衍生物和PDE 4抑制剂的用途的组合物。
-
公开(公告)号：EP3858825A1
公开(公告)日：2021-08-04
申请号：EP21157042.9
申请日：2016-08-16
申请人： Pfizer Inc.
发明人： LEE, Katherine Lin , ALLAIS, Christophe Philippe , DEHNHARDT, Christoph Martin , GAVRIN, Lori Krim , HAN, Seungil , HEPWORTH, David , LEE, Arthur , LOVERING, Frank Eldridge , MATHIAS, John Paul , OWEN, Dafydd Rhys , PAPAIOANNOU, Nikolaos , SAIAH, Eddine , STROHBACH, Joseph Walter , TRZUPEK, John David , WRIGHT, Stephen Wayne , ZAPF, Christoph Wolfgang
IPC分类号： C07D401/12 , C07D413/14 , C07D401/14 , C07D491/18 , C07D471/04 , A61K31/4709 , A61K31/4725 , A61K31/4375 , C07D207/273 , A61P29/00 , A61P11/00 , A61P35/00 , A61P25/00
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula IIc to IIi, IIl to IIv or IIx as defined in the claims. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：EP3536685A1
公开(公告)日：2019-09-11
申请号：EP19157789.9
申请日：2015-03-26
申请人： Pfizer Inc.
发明人： ANDERSON, David Randolph , BUNNAGE, Mark Edward , CURRAN, Kevin Joseph , DEHNHARDT, Christoph Martin , GAVRIN, Lori Krim , GOLDBERG, Joel Adam , HAN, Seungil , HEPWORTH, David , HUANG, Horng-Chih , LEE, Arthur , LEE, Katherine Lin , LOVERING, Frank Eldridge , LOWE, Michael Dennis , MATHIAS, John Paul , PAPAIOANNOU, Nikolaos , PATNY, Akshay , PIERCE, Betsy Susan , SAIAH, Eddine , STROHBACH, Joseph Walter , TRZUPEK, John David , VARGAS, Richard , WANG, Xiaolun , WRIGHT, Stephen Wayne , ZAPF, Christoph Wolfgang
IPC分类号： C07D207/26
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia ,
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment of autoimmune and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), methods of synthesis, and intermediates are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.022 秒)
